Global Neuroprotection Drugs Market By Drugs Type (Antidepressants, Antiepileptic, Antipsychotic, Anti-inflammatory, Anesthetics, Antagonists, Antibiotics, Antidepressants, Antioxidants, Cytokines, Ion Channel Blockers, Neurosteroids, Nutraceuticals, Pathway Inhibitors and Others (Vaccines, Toxins, etc.)), By Application (Cerebrovascular Disease (Ischemic Stroke, Hemorrhagic Stroke, cerebrovascular anomalies(intracranial aneurysms and arteriovenous malformations), Neurodegenerative Disorders (Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis, Progressive supranuclear palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD), Dementia With Lewy Bodies (DLB) Others (Multiple System Atrophy (MSA), Chronic Traumatic Encephalopathy (CTE), Etc.), Traumatic CNS Injuries (Coup-Contrecoup Brain Injury, Concussion, Brain Concussion, Diffuse Axonal Injury, Penetrating Injury, Second Impact Syndrome, Others); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027

Report ID :AMI-229 | Category : Healthcare | Published Date : July, 2019 | Pages : 211 | Format :PDF
Buy Now!

Industry Trends

Global Neuroprotection drugs market was valued at US$ 28,908.7 million in 2018 and is estimated to reach US$ 33,481.7 million by 2027, growing at an estimated CAGR of 1.56 % over the next eight years. Rising incidences of cerebral stroke and other severe disorders such as Alzheimer’s disease, epilepsy, and Parkinsonism is expected to fuel demand of neuroprotective drugs market thereby driving the overall neuroscience industry growth. Strokes are the major cause of distress in the industrialized countries and ischemic stroke is one of the greatest causes for disability. An ischemic stroke happens when a cerebral vessel impedes, obstructing streaming of blood to a portion of the brain. With a maturing populace, putative medicines for ischemic stroke are required to constrain the degree of stroke-actuated dismalness and mortality. Parkinson’s disease (PD) and Alzheimer's disease (AD) are extreme neurodegenerative disorders. Neuroprotective drugs will be required for the treatment of these strokes and disorders. Moreover, neuroprotection drugs such as erythropoietin (EPO) have the potential to reduce generalized brain injury caused commonly by brain tumor treatment. Such incidences and its successive factors is anticipated to propel the global neuroprotection drugs market over the forecast period.

Neuroprotection, mainly referred as the “protection of neurons” is a type of medication defined as an effect that may result in salvage, recovery or regeneration of the nervous system, its cell, structure and function. Neuroprotection drugs also protects the brain from secondary injury in the immediate period of trauma.

Failure of drug delivery is one of the major restraints in the global neuroprotection drugs market. Drugs travelling in the bloodstream may be unable to reach the targeted area of the cerebrum, either because of poor perfusion of ischemic tissues or inability to cross the blood–brain barrier. Furthermore, side effects of specific drugs can counteract administration of successful dosages that are proportional to those utilized in preclinical studies.

A class of novel cyclic dipeptides (diketopiperazines), structurally like a physiologically dynamic metabolic result of thyrotropin-releasing hormone, have appeared in neuronal cell cultures against oxygen and/or glucose hardship, free radical damage, excitotoxicity, mechanical injury, and various proapoptotic and pronecrotic affronts, likewise extraordinarily lessening sore volume and improving motor and cognitive results over numerous species and models of brain injury.

By drug type, antidepressants has the highest penetration in 2018 and is expected continue the same trend over the forecast period. Antidepressants are an important category of neuroprotection drugs market that can help relieve indications of anxiety disorders, depression, dysthymia, or mild chronic depression, and other such conditions. The primary objective of antidepressants is to correct chemical imbalances of neurotransmitters in the cerebrum that are responsible for changes in one's mood and behavior. Chemical antidepressants mostly include monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and selective norepinephrine reuptake inhibitors (SNRIs). Therapeutic applications received from the same can be felt immediately or in some cases, it is observed after few days or often not until 3 weeks. Nonchemical antidepressants such as electroconvulsive therapy (ECT) and physical exercise are some ways that tend to employ similar therapeutic mechanisms.

Neurodegenerative disorders segment exhibited the largest share in 2018, accounting for more than 60% of the global neuroprotection drugs market. Neurodegenerative disorders are caused by the dynamic demise of neurons in various regions of the brain. The dynamic loss of nerve cells is what gives rise to the neurological and neuropsychological signs and symptoms for each of these diseases. Neurodegenerative disorders affect a large number of individuals around the world, the most common types being Alzheimer's disease and Parkinson's disease. A drug named Selegiline, discovered by Cardinal Health Inc, is a neuroprotectant can be use for disease indications such as cerebrovascular ischemia and Parkinson’s disease.

Europe had the largest market share for the year 2018 that accounted over 30% of the overall neuroprotection drugs market. In a recent study by European public assessment report (EPAR), the established efficacy result achieved by Mirapexin has been reported. It is available as immediate release white tablets and prolonged release white tablets. The same is used to treat symptoms of Parkinson’s disease. The medication can be either used solely or can be used in combination with levodopa. The starting dose is either one 0.088-mg immediate-release tablet thrice a day or one 0.26-mg prolonged-release tablet, only one time per day. The dose should be increased every six to seven days until the symptoms are controlled. This should also be associated without causing side effects. It is less effective for patients suffering from kidney diseases.

North America, Neuroprotection Drugs Market Revenue & Forecast, (US$ Million), 2015 – 2027

Neuroprotection Drugs Market

Competitive Landscape

The report provides both, qualitative and quantitative research of patient recliners market, market, as well as provides comprehensive insights and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, specification, pricing, and gross margin.

Some of the players operating in the neuroprotection drugs market are F. Hoffmann-La Roche Ltd., Genervon Biopharmaceuticals LLC, Bionure Farma S.L., Biogen, Inc., Astrocyte Pharmaceuticals, Inc., AstraZeneca PLC, Neuren Pharmaceuticals Ltd., Novartis Pharmaceuticals Corporation, Teva Pharmaceutical Industries Ltd. amongst others.

Neuroprotection Drugs Market:

  • By Drugs Type
    • Anesthetics
    • Antagonists 
    • Antibiotics
    • Antidepressants
    • Antiepileptic agents
    • Anti-inflammatory agents
    • Antioxidants/free radical scavengers
    • Cytokines
    • Ion Channel Blockers
    • Neurosteroids
    • Nutraceuticals
    • Pathway Inhibitor
    • Others (Vaccines, Toxins, etc.)  
  • By Application
    • Cerebrovascular Disease
      • ischemic stroke
      • hemorrhagic stroke
      • cerebrovascular anomalies
        • intracranial aneurysms
        • arteriovenous malformations
    • Neurodegenerative Disorders
      • Alzheimer’s Disease
      • Parkinson’s Disease
      • Amyotrophic Lateral Sclerosis
      • Progressive supranuclear palsy (PSP)
      • Corticobasal Degeneration (CBD)
      • Frontotemporal Dementia (FTD)
      • Dementia With Lewy Bodies (DLB)
      • Huntington’s Disease (HD)
      • Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
    • Traumatic CNS Injuries
      • Coup-Contrecoup Brain Injury
      • Concussion
      • Brain Contusion
      • Diffuse Axonal Injury
      • Penetrating Injury
      • Second Impact Syndrome
      • Others
    • Others
  • By Geography
    • North America
      • U.S.
      • Canada
      • Mexico
      • Rest of North America
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
      • Benelux Union
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • New Zealand
      • Southeast Asia
      • Rest of Asia Pacific
    • Middle East and Africa
      • GCC Countries
      • Southern Africa
      • Rest of Middle East and Africa
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America

Key Questions

Request Sample

Report Customization

Request for Customization

1. Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2013 - 2017

1.2.2. Base Year: 2018

1.2.3. Forecast Years: 2019 – 2027

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMI’s Perspective**

5. Holistic Overview of Neuroprotection Drugs Market

6. Market Synopsis:  Neuroprotection Drugs Market

7. Neuroprotection Drugs Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.2.4. Challenges

7.3. Trends in Neuroprotection Drugs Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Neuroprotection Drugs Market

7.6. Porter’s Five Force Analysis

8. Global Neuroprotection Drugs Market Analysis and Forecasts, 2019 – 2027

8.1. Overview

8.1.1. Global Neuroprotection Drugs Market Revenue (US$ Mn)

8.2. Global Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

8.2.1. Anesthetics

8.2.1.1. Definition

8.2.1.2. Market Penetration, 2018

8.2.1.3. Market Estimation, 2013 – 2018

8.2.1.4. Market Forecast, 2019 – 2027

8.2.1.5. Compound Annual Growth Rate (CAGR)

8.2.1.6. Regional Bifurcation

8.2.1.6.1. North America

8.2.1.6.1.1. Market Estimation, 2013 – 2018

8.2.1.6.1.2. Market Forecast, 2019 – 2027

8.2.1.6.2. Europe

8.2.1.6.2.1. Market Estimation, 2013 – 2018

8.2.1.6.2.2. Market Forecast, 2019 – 2027

8.2.1.6.3. Asia Pacific

8.2.1.6.3.1. Market Estimation, 2013 – 2018

8.2.1.6.3.2. Market Forecast, 2019 – 2027

8.2.1.6.4. Middle East and Africa

8.2.1.6.4.1. Market Estimation, 2013 – 2018

8.2.1.6.4.2. Market Forecast, 2019 – 2027

8.2.1.6.5. Latin America

8.2.1.6.5.1. Market Estimation, 2013 – 2018

8.2.1.6.5.2. Market Forecast, 2019 – 2027

8.2.2. Antagonists

8.2.2.1. Definition

8.2.2.2. Market Penetration, 2018

8.2.2.3. Market Estimation, 2013 – 2018

8.2.2.4. Market Forecast, 2019 – 2027

8.2.2.5. Compound Annual Growth Rate (CAGR)

8.2.2.6. Regional Bifurcation

8.2.2.6.1. North America

8.2.2.6.1.1. Market Estimation, 2013 – 2018

8.2.2.6.1.2. Market Forecast, 2019 – 2027

8.2.2.6.2. Europe

8.2.2.6.2.1. Market Estimation, 2013 – 2018

8.2.2.6.2.2. Market Forecast, 2019 – 2027

8.2.2.6.3. Asia Pacific

8.2.2.6.3.1. Market Estimation, 2013 – 2018

8.2.2.6.3.2. Market Forecast, 2019 – 2027

8.2.2.6.4. Middle East and Africa

8.2.2.6.4.1. Market Estimation, 2013 – 2018

8.2.2.6.4.2. Market Forecast, 2019 – 2027

8.2.2.6.5. Latin America

8.2.2.6.5.1. Market Estimation, 2013 – 2018

8.2.2.6.5.2. Market Forecast, 2019 – 2027

8.2.3. Antibiotics

8.2.3.1. Definition

8.2.3.2. Market Penetration, 2018

8.2.3.3. Market Estimation, 2013 – 2018

8.2.3.4. Market Forecast, 2019 – 2027

8.2.3.5. Compound Annual Growth Rate (CAGR)

8.2.3.6. Regional Bifurcation

8.2.3.6.1. North America

8.2.3.6.1.1. Market Estimation, 2013 – 2018

8.2.3.6.1.2. Market Forecast, 2019 – 2027

8.2.3.6.2. Europe

8.2.3.6.2.1. Market Estimation, 2013 – 2018

8.2.3.6.2.2. Market Forecast, 2019 – 2027

8.2.3.6.3. Asia Pacific

8.2.3.6.3.1. Market Estimation, 2013 – 2018

8.2.3.6.3.2. Market Forecast, 2019 – 2027

8.2.3.6.4. Middle East and Africa

8.2.3.6.4.1. Market Estimation, 2013 – 2018

8.2.3.6.4.2. Market Forecast, 2019 – 2027

8.2.3.6.5. Latin America

8.2.3.6.5.1. Market Estimation, 2013 – 2018

8.2.3.6.5.2. Market Forecast, 2019 – 2027

8.2.4. Antidepressants

8.2.4.1. Definition

8.2.4.2. Market Penetration, 2018

8.2.4.3. Market Estimation, 2013 – 2018

8.2.4.4. Market Forecast, 2019 – 2027

8.2.4.5. Compound Annual Growth Rate (CAGR)

8.2.4.6. Regional Bifurcation

8.2.4.6.1. North America

8.2.4.6.1.1. Market Estimation, 2013 – 2018

8.2.4.6.1.2. Market Forecast, 2019 – 2027

8.2.4.6.2. Europe

8.2.4.6.2.1. Market Estimation, 2013 – 2018

8.2.4.6.2.2. Market Forecast, 2019 – 2027

8.2.4.6.3. Asia Pacific

8.2.4.6.3.1. Market Estimation, 2013 – 2018

8.2.4.6.3.2. Market Forecast, 2019 – 2027

8.2.4.6.4. Middle East and Africa

8.2.4.6.4.1. Market Estimation, 2013 – 2018

8.2.4.6.4.2. Market Forecast, 2019 – 2027

8.2.4.6.5. Latin America

8.2.4.6.5.1. Market Estimation, 2013 – 2018

8.2.4.6.5.2. Market Forecast, 2019 – 2027

8.2.5. Antiepileptic agents

8.2.5.1. Definition

8.2.5.2. Market Penetration, 2018

8.2.5.3. Market Estimation, 2013 – 2018

8.2.5.4. Market Forecast, 2019 – 2027

8.2.5.5. Compound Annual Growth Rate (CAGR)

8.2.5.6. Regional Bifurcation

8.2.5.6.1. North America

8.2.5.6.1.1. Market Estimation, 2013 – 2018

8.2.5.6.1.2. Market Forecast, 2019 – 2027

8.2.5.6.2. Europe

8.2.5.6.2.1. Market Estimation, 2013 – 2018

8.2.5.6.2.2. Market Forecast, 2019 – 2027

8.2.5.6.3. Asia Pacific

8.2.5.6.3.1. Market Estimation, 2013 – 2018

8.2.5.6.3.2. Market Forecast, 2019 – 2027

8.2.5.6.4. Middle East and Africa

8.2.5.6.4.1. Market Estimation, 2013 – 2018

8.2.5.6.4.2. Market Forecast, 2019 – 2027

8.2.5.6.5. Latin America

8.2.5.6.5.1. Market Estimation, 2013 – 2018

8.2.5.6.5.2. Market Forecast, 2019 – 2027

8.2.6. Anti-inflammatory agents

8.2.6.1. Definition

8.2.6.2. Market Penetration, 2018

8.2.6.3. Market Estimation, 2013 – 2018

8.2.6.4. Market Forecast, 2019 – 2027

8.2.6.5. Compound Annual Growth Rate (CAGR)

8.2.6.6. Regional Bifurcation

8.2.6.6.1. North America

8.2.6.6.1.1. Market Estimation, 2013 – 2018

8.2.6.6.1.2. Market Forecast, 2019 – 2027

8.2.6.6.2. Europe

8.2.6.6.2.1. Market Estimation, 2013 – 2018

8.2.6.6.2.2. Market Forecast, 2019 – 2027

8.2.6.6.3. Asia Pacific

8.2.6.6.3.1. Market Estimation, 2013 – 2018

8.2.6.6.3.2. Market Forecast, 2019 – 2027

8.2.6.6.4. Middle East and Africa

8.2.6.6.4.1. Market Estimation, 2013 – 2018

8.2.6.6.4.2. Market Forecast, 2019 – 2027

8.2.6.6.5. Latin America

8.2.6.6.5.1. Market Estimation, 2013 – 2018

8.2.6.6.5.2. Market Forecast, 2019 – 2027

8.2.7. Antioxidants/free radical scavengers

8.2.7.1. Definition

8.2.7.2. Market Penetration, 2018

8.2.7.3. Market Estimation, 2013 – 2018

8.2.7.4. Market Forecast, 2019 – 2027

8.2.7.5. Compound Annual Growth Rate (CAGR)

8.2.7.6. Regional Bifurcation

8.2.7.6.1. North America

8.2.7.6.1.1. Market Estimation, 2013 – 2018

8.2.7.6.1.2. Market Forecast, 2019 – 2027

8.2.7.6.2. Europe

8.2.7.6.2.1. Market Estimation, 2013 – 2018

8.2.7.6.2.2. Market Forecast, 2019 – 2027

8.2.7.6.3. Asia Pacific

8.2.7.6.3.1. Market Estimation, 2013 – 2018

8.2.7.6.3.2. Market Forecast, 2019 – 2027

8.2.7.6.4. Middle East and Africa

8.2.7.6.4.1. Market Estimation, 2013 – 2018

8.2.7.6.4.2. Market Forecast, 2019 – 2027

8.2.7.6.5. Latin America

8.2.7.6.5.1. Market Estimation, 2013 – 2018

8.2.7.6.5.2. Market Forecast, 2019 – 2027

8.2.8. Cytokines

8.2.8.1. Definition

8.2.8.2. Market Penetration, 2018

8.2.8.3. Market Estimation, 2013 – 2018

8.2.8.4. Market Forecast, 2019 – 2027

8.2.8.5. Compound Annual Growth Rate (CAGR)

8.2.8.6. Regional Bifurcation

8.2.8.6.1. North America

8.2.8.6.1.1. Market Estimation, 2013 – 2018

8.2.8.6.1.2. Market Forecast, 2019 – 2027

8.2.8.6.2. Europe

8.2.8.6.2.1. Market Estimation, 2013 – 2018

8.2.8.6.2.2. Market Forecast, 2019 – 2027

8.2.8.6.3. Asia Pacific

8.2.8.6.3.1. Market Estimation, 2013 – 2018

8.2.8.6.3.2. Market Forecast, 2019 – 2027

8.2.8.6.4. Middle East and Africa

8.2.8.6.4.1. Market Estimation, 2013 – 2018

8.2.8.6.4.2. Market Forecast, 2019 – 2027

8.2.8.6.5. Latin America

8.2.8.6.5.1. Market Estimation, 2013 – 2018

8.2.8.6.5.2. Market Forecast, 2019 – 2027

8.2.9. Ion Channel Blockers

8.2.9.1. Definition

8.2.9.2. Market Penetration, 2018

8.2.9.3. Market Estimation, 2013 – 2018

8.2.9.4. Market Forecast, 2019 – 2027

8.2.9.5. Compound Annual Growth Rate (CAGR)

8.2.9.6. Regional Bifurcation

8.2.9.6.1. North America

8.2.9.6.1.1. Market Estimation, 2013 – 2018

8.2.9.6.1.2. Market Forecast, 2019 – 2027

8.2.9.6.2. Europe

8.2.9.6.2.1. Market Estimation, 2013 – 2018

8.2.9.6.2.2. Market Forecast, 2019 – 2027

8.2.9.6.3. Asia Pacific

8.2.9.6.3.1. Market Estimation, 2013 – 2018

8.2.9.6.3.2. Market Forecast, 2019 – 2027

8.2.9.6.4. Middle East and Africa

8.2.9.6.4.1. Market Estimation, 2013 – 2018

8.2.9.6.4.2. Market Forecast, 2019 – 2027

8.2.9.6.5. Latin America

8.2.9.6.5.1. Market Estimation, 2013 – 2018

8.2.9.6.5.2. Market Forecast, 2019 – 2027

8.2.10. Neurosteroids

8.2.10.1. Definition

8.2.10.2. Market Penetration, 2018

8.2.10.3. Market Estimation, 2013 – 2018

8.2.10.4. Market Forecast, 2019 – 2027

8.2.10.5. Compound Annual Growth Rate (CAGR)

8.2.10.6. Regional Bifurcation

8.2.10.6.1. North America

8.2.10.6.1.1. Market Estimation, 2013 – 2018

8.2.10.6.1.2. Market Forecast, 2019 – 2027

8.2.10.6.2. Europe

8.2.10.6.2.1. Market Estimation, 2013 – 2018

8.2.10.6.2.2. Market Forecast, 2019 – 2027

8.2.10.6.3. Asia Pacific

8.2.10.6.3.1. Market Estimation, 2013 – 2018

8.2.10.6.3.2. Market Forecast, 2019 – 2027

8.2.10.6.4. Middle East and Africa

8.2.10.6.4.1. Market Estimation, 2013 – 2018

8.2.10.6.4.2. Market Forecast, 2019 – 2027

8.2.10.6.5. Latin America

8.2.10.6.5.1. Market Estimation, 2013 – 2018

8.2.10.6.5.2. Market Forecast, 2019 – 2027

8.2.11. Nutraceuticals

8.2.11.1. Definition

8.2.11.2. Market Penetration, 2018

8.2.11.3. Market Estimation, 2013 – 2018

8.2.11.4. Market Forecast, 2019 – 2027

8.2.11.5. Compound Annual Growth Rate (CAGR)

8.2.11.6. Regional Bifurcation

8.2.11.6.1. North America

8.2.11.6.1.1. Market Estimation, 2013 – 2018

8.2.11.6.1.2. Market Forecast, 2019 – 2027

8.2.11.6.2. Europe

8.2.11.6.2.1. Market Estimation, 2013 – 2018

8.2.11.6.2.2. Market Forecast, 2019 – 2027

8.2.11.6.3. Asia Pacific

8.2.11.6.3.1. Market Estimation, 2013 – 2018

8.2.11.6.3.2. Market Forecast, 2019 – 2027

8.2.11.6.4. Middle East and Africa

8.2.11.6.4.1. Market Estimation, 2013 – 2018

8.2.11.6.4.2. Market Forecast, 2019 – 2027

8.2.11.6.5. Latin America

8.2.11.6.5.1. Market Estimation, 2013 – 2018

8.2.11.6.5.2. Market Forecast, 2019 – 2027

8.2.12. Pathway Inhibitor

8.2.12.1. Definition

8.2.12.2. Market Penetration, 2018

8.2.12.3. Market Estimation, 2013 – 2018

8.2.12.4. Market Forecast, 2019 – 2027

8.2.12.5. Compound Annual Growth Rate (CAGR)

8.2.12.6. Regional Bifurcation

8.2.12.6.1. North America

8.2.12.6.1.1. Market Estimation, 2013 – 2018

8.2.12.6.1.2. Market Forecast, 2019 – 2027

8.2.12.6.2. Europe

8.2.12.6.2.1. Market Estimation, 2013 – 2018

8.2.12.6.2.2. Market Forecast, 2019 – 2027

8.2.12.6.3. Asia Pacific

8.2.12.6.3.1. Market Estimation, 2013 – 2018

8.2.12.6.3.2. Market Forecast, 2019 – 2027

8.2.12.6.4. Middle East and Africa

8.2.12.6.4.1. Market Estimation, 2013 – 2018

8.2.12.6.4.2. Market Forecast, 2019 – 2027

8.2.12.6.5. Latin America

8.2.12.6.5.1. Market Estimation, 2013 – 2018

8.2.12.6.5.2. Market Forecast, 2019 – 2027

8.2.13. Others (Vaccines, Toxins, etc.)

8.2.13.1. Definition

8.2.13.2. Market Penetration, 2018

8.2.13.3. Market Estimation, 2013 – 2018

8.2.13.4. Market Forecast, 2019 – 2027

8.2.13.5. Compound Annual Growth Rate (CAGR)

8.2.13.6. Regional Bifurcation

8.2.13.6.1. North America

8.2.13.6.1.1. Market Estimation, 2013 – 2018

8.2.13.6.1.2. Market Forecast, 2019 – 2027

8.2.13.6.2. Europe

8.2.13.6.2.1. Market Estimation, 2013 – 2018

8.2.13.6.2.2. Market Forecast, 2019 – 2027

8.2.13.6.3. Asia Pacific

8.2.13.6.3.1. Market Estimation, 2013 – 2018

8.2.13.6.3.2. Market Forecast, 2019 – 2027

8.2.13.6.4. Middle East and Africa

8.2.13.6.4.1. Market Estimation, 2013 – 2018

8.2.13.6.4.2. Market Forecast, 2019 – 2027

8.2.13.6.5. Latin America

8.2.13.6.5.1. Market Estimation, 2013 – 2018

8.2.13.6.5.2. Market Forecast, 2019 – 2027

8.3. Key Segment for Channeling Investments

8.3.1. By Drugs Type

9. Global Neuroprotection Drugs Market Analysis and Forecasts, 2019 – 2027

9.1. Overview

9.2. Global Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

9.2.1. Cerebrovascular Disease (Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on ischemic stroke, hemorrhagic stroke, cerebrovascular anomalies)

9.2.1.1. ischemic stroke

9.2.1.2. hemorrhagic stroke

9.2.1.3. cerebrovascular anomalies

9.2.1.3.1. intracranial aneurysms

9.2.1.3.2. arteriovenous malformations

9.2.2. Neurodegenerative Disorders (Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Progressive supranuclear palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD), Dementia With Lewy Bodies (DLB), Huntington’s Disease (HD), Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.))

9.2.2.1. Alzheimer’s Disease

9.2.2.2. Parkinson’s Disease

9.2.2.3. Amyotrophic Lateral Sclerosis

9.2.2.4. Progressive supranuclear palsy (PSP)

9.2.2.5. Corticobasal Degeneration (CBD)

9.2.2.6. Frontotemporal Dementia (FTD)

9.2.2.7. Dementia With Lewy Bodies (DLB)

9.2.2.8. Huntington’s Disease (HD)

9.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

9.2.3. Traumatic CNS Injuries (Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Coup-Contrecoup Brain Injury, Concussion, Brain Contusion, Diffuse Axonal Injury, Penetrating Injury, Second Impact Syndrome, Others)

9.2.3.1. Coup-Contrecoup Brain Injury

9.2.3.2. Concussion

9.2.3.3. Brain Contusion

9.2.3.4. Diffuse Axonal Injury

9.2.3.5. Penetrating Injury

9.2.3.6. Second Impact Syndrome

9.2.3.7. Others

9.2.4. Others

9.2.4.1. Definition

9.2.4.2. Market Penetration, 2018

9.2.4.3. Market Estimation, 2013 – 2018

9.2.4.4. Market Forecast, 2019 – 2027

9.2.4.5. Compound Annual Growth Rate (CAGR)

9.2.4.6. Regional Bifurcation

9.2.4.6.1. North America

9.2.4.6.1.1. Market Estimation, 2013 – 2018

9.2.4.6.1.2. Market Forecast, 2019 – 2027

9.2.4.6.2. Europe

9.2.4.6.2.1. Market Estimation, 2013 – 2018

9.2.4.6.2.2. Market Forecast, 2019 – 2027

9.2.4.6.3. Asia Pacific

9.2.4.6.3.1. Market Estimation, 2013 – 2018

9.2.4.6.3.2. Market Forecast, 2019 – 2027

9.2.4.6.4. Middle East and Africa

9.2.4.6.4.1. Market Estimation, 2013 – 2018

9.2.4.6.4.2. Market Forecast, 2019 – 2027

9.2.4.6.5. Latin America

9.2.4.6.5.1. Market Estimation, 2013 – 2018

9.2.4.6.5.2. Market Forecast, 2019 – 2027

9.3. Key Segment for Channeling Investments

9.3.1. By Application

10. North America Neuroprotection Drugs Market Analysis and Forecasts, 2019 - 2027

10.1. Overview

10.1.1. North America Neuroprotection Drugs Market Revenue (US$ Mn)

10.2. North America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

10.2.1. Anesthetics

10.2.2. Antagonists

10.2.3. Antibiotics

10.2.4. Antidepressants

10.2.5. Antiepileptic agents

10.2.6. Anti-inflammatory agents

10.2.7. Antioxidants/free radical scavengers

10.2.8. Cytokines

10.2.9. Ion Channel Blockers

10.2.10. Neurosteroids

10.2.11. Nutraceuticals

10.2.12. Pathway Inhibitor

10.2.13. Others (Vaccines, Toxins, etc.)

10.3. North America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

10.3.1. Cerebrovascular Disease

10.3.1.1. ischemic stroke

10.3.1.2. hemorrhagic stroke

10.3.1.3. cerebrovascular anomalies

10.3.1.3.1. intracranial aneurysms

10.3.1.3.2. arteriovenous malformations

10.3.2. Neurodegenerative Disorders

10.3.2.1. Alzheimer’s Disease

10.3.2.2. Parkinson’s Disease

10.3.2.3. Amyotrophic Lateral Sclerosis

10.3.2.4. Progressive supranuclear palsy (PSP)

10.3.2.5. Corticobasal Degeneration (CBD)

10.3.2.6. Frontotemporal Dementia (FTD)

10.3.2.7. Dementia With Lewy Bodies (DLB)

10.3.2.8. Huntington’s Disease (HD)

10.3.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

10.3.3. Traumatic CNS Injuries

10.3.3.1. Coup-Contrecoup Brain Injury

10.3.3.2. Concussion

10.3.3.3. Brain Contusion

10.3.3.4. Diffuse Axonal Injury

10.3.3.5. Penetrating Injury

10.3.3.6. Second Impact Syndrome

10.3.3.7. Others

10.3.4. Others

10.4. North America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. U.S

10.4.1.1. U.S Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

10.4.1.1.1. Anesthetics

10.4.1.1.2. Antagonists

10.4.1.1.3. Antibiotics

10.4.1.1.4. Antidepressants

10.4.1.1.5. Antiepileptic agents

10.4.1.1.6. Anti-inflammatory agents

10.4.1.1.7. Antioxidants/free radical scavengers

10.4.1.1.8. Cytokines

10.4.1.1.9. Ion Channel Blockers

10.4.1.1.10. Neurosteroids

10.4.1.1.11. Nutraceuticals

10.4.1.1.12. Pathway Inhibitor

10.4.1.1.13. Others (Vaccines, Toxins, etc.)

10.4.1.2. U.S Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

10.4.1.2.1. Cerebrovascular Disease

10.4.1.2.1.1. ischemic stroke

10.4.1.2.1.2. hemorrhagic stroke

10.4.1.2.1.3. cerebrovascular anomalies

10.4.1.2.1.3.1. intracranial aneurysms

10.4.1.2.1.3.2. arteriovenous malformations

10.4.1.2.2. Neurodegenerative Disorders

10.4.1.2.2.1. Alzheimer’s Disease

10.4.1.2.2.2. Parkinson’s Disease

10.4.1.2.2.3. Amyotrophic Lateral Sclerosis

10.4.1.2.2.4. Progressive supranuclear palsy (PSP)

10.4.1.2.2.5. Corticobasal Degeneration (CBD)

10.4.1.2.2.6. Frontotemporal Dementia (FTD)

10.4.1.2.2.7. Dementia With Lewy Bodies (DLB)

10.4.1.2.2.8. Huntington’s Disease (HD)

10.4.1.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

10.4.1.2.3. Traumatic CNS Injuries

10.4.1.2.3.1. Coup-Contrecoup Brain Injury

10.4.1.2.3.2. Concussion

10.4.1.2.3.3. Brain Contusion

10.4.1.2.3.4. Diffuse Axonal Injury

10.4.1.2.3.5. Penetrating Injury

10.4.1.2.3.6. Second Impact Syndrome

10.4.1.2.3.7. Others

10.4.1.2.4. Others

10.4.2. Canada

10.4.2.1. Canada Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

10.4.2.1.1. Anesthetics

10.4.2.1.2. Antagonists

10.4.2.1.3. Antibiotics

10.4.2.1.4. Antidepressants

10.4.2.1.5. Antiepileptic agents

10.4.2.1.6. Anti-inflammatory agents

10.4.2.1.7. Antioxidants/free radical scavengers

10.4.2.1.8. Cytokines

10.4.2.1.9. Ion Channel Blockers

10.4.2.1.10. Neurosteroids

10.4.2.1.11. Nutraceuticals

10.4.2.1.12. Pathway Inhibitor

10.4.2.1.13. Others (Vaccines, Toxins, etc.)

10.4.2.2. Canada Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

10.4.2.2.1. Cerebrovascular Disease

10.4.2.2.1.1. ischemic stroke

10.4.2.2.1.2. hemorrhagic stroke

10.4.2.2.1.3. cerebrovascular anomalies

10.4.2.2.1.3.1. intracranial aneurysms

10.4.2.2.1.3.2. arteriovenous malformations

10.4.2.2.2. Neurodegenerative Disorders

10.4.2.2.2.1. Alzheimer’s Disease

10.4.2.2.2.2. Parkinson’s Disease

10.4.2.2.2.3. Amyotrophic Lateral Sclerosis

10.4.2.2.2.4. Progressive supranuclear palsy (PSP)

10.4.2.2.2.5. Corticobasal Degeneration (CBD)

10.4.2.2.2.6. Frontotemporal Dementia (FTD)

10.4.2.2.2.7. Dementia With Lewy Bodies (DLB)

10.4.2.2.2.8. Huntington’s Disease (HD)

10.4.2.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

10.4.2.2.3. Traumatic CNS Injuries

10.4.2.2.3.1. Coup-Contrecoup Brain Injury

10.4.2.2.3.2. Concussion

10.4.2.2.3.3. Brain Contusion

10.4.2.2.3.4. Diffuse Axonal Injury

10.4.2.2.3.5. Penetrating Injury

10.4.2.2.3.6. Second Impact Syndrome

10.4.2.2.3.7. Others

10.4.2.2.4. Others

10.4.3. Mexico

10.4.3.1. Mexico Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

10.4.3.1.1. Anesthetics

10.4.3.1.2. Antagonists

10.4.3.1.3. Antibiotics

10.4.3.1.4. Antidepressants

10.4.3.1.5. Antiepileptic agents

10.4.3.1.6. Anti-inflammatory agents

10.4.3.1.7. Antioxidants/free radical scavengers

10.4.3.1.8. Cytokines

10.4.3.1.9. Ion Channel Blockers

10.4.3.1.10. Neurosteroids

10.4.3.1.11. Nutraceuticals

10.4.3.1.12. Pathway Inhibitor

10.4.3.1.13. Others (Vaccines, Toxins, etc.)

10.4.3.2. Mexico Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

10.4.3.2.1. Cerebrovascular Disease

10.4.3.2.1.1. ischemic stroke

10.4.3.2.1.2. hemorrhagic stroke

10.4.3.2.1.3. cerebrovascular anomalies

10.4.3.2.1.3.1. intracranial aneurysms

10.4.3.2.1.3.2. arteriovenous malformations

10.4.3.2.2. Neurodegenerative Disorders

10.4.3.2.2.1. Alzheimer’s Disease

10.4.3.2.2.2. Parkinson’s Disease

10.4.3.2.2.3. Amyotrophic Lateral Sclerosis

10.4.3.2.2.4. Progressive supranuclear palsy (PSP)

10.4.3.2.2.5. Corticobasal Degeneration (CBD)

10.4.3.2.2.6. Frontotemporal Dementia (FTD)

10.4.3.2.2.7. Dementia With Lewy Bodies (DLB)

10.4.3.2.2.8. Huntington’s Disease (HD)

10.4.3.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

10.4.3.2.3. Traumatic CNS Injuries

10.4.3.2.3.1. Coup-Contrecoup Brain Injury

10.4.3.2.3.2. Concussion

10.4.3.2.3.3. Brain Contusion

10.4.3.2.3.4. Diffuse Axonal Injury

10.4.3.2.3.5. Penetrating Injury

10.4.3.2.3.6. Second Impact Syndrome

10.4.3.2.3.7. Others

10.4.3.2.4. Others

10.4.4. Rest of North America

10.4.4.1. Rest of North America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

10.4.4.1.1. Anesthetics

10.4.4.1.2. Antagonists

10.4.4.1.3. Antibiotics

10.4.4.1.4. Antidepressants

10.4.4.1.5. Antiepileptic agents

10.4.4.1.6. Anti-inflammatory agents

10.4.4.1.7. Antioxidants/free radical scavengers

10.4.4.1.8. Cytokines

10.4.4.1.9. Ion Channel Blockers

10.4.4.1.10. Neurosteroids

10.4.4.1.11. Nutraceuticals

10.4.4.1.12. Pathway Inhibitor

10.4.4.1.13. Others (Vaccines, Toxins, etc.)

10.4.4.2. Rest of North America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

10.4.4.2.1. Cerebrovascular Disease

10.4.4.2.1.1. ischemic stroke

10.4.4.2.1.2. hemorrhagic stroke

10.4.4.2.1.3. cerebrovascular anomalies

10.4.4.2.1.3.1. intracranial aneurysms

10.4.4.2.1.3.2. arteriovenous malformations

10.4.4.2.2. Neurodegenerative Disorders

10.4.4.2.2.1. Alzheimer’s Disease

10.4.4.2.2.2. Parkinson’s Disease

10.4.4.2.2.3. Amyotrophic Lateral Sclerosis

10.4.4.2.2.4. Progressive supranuclear palsy (PSP)

10.4.4.2.2.5. Corticobasal Degeneration (CBD)

10.4.4.2.2.6. Frontotemporal Dementia (FTD)

10.4.4.2.2.7. Dementia With Lewy Bodies (DLB)

10.4.4.2.2.8. Huntington’s Disease (HD)

10.4.4.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

10.4.4.2.3. Traumatic CNS Injuries

10.4.4.2.3.1. Coup-Contrecoup Brain Injury

10.4.4.2.3.2. Concussion

10.4.4.2.3.3. Brain Contusion

10.4.4.2.3.4. Diffuse Axonal Injury

10.4.4.2.3.5. Penetrating Injury

10.4.4.2.3.6. Second Impact Syndrome

10.4.4.2.3.7. Others

10.4.4.2.4. Others

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Drugs Type

10.5.3. By Application

11. Europe Neuroprotection Drugs Market Analysis and Forecasts, 2019 - 2027

11.1. Overview

11.1.1. Europe Neuroprotection Drugs Market Revenue (US$ Mn)

11.2. Europe Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

11.2.1. Anesthetics

11.2.2. Antagonists

11.2.3. Antibiotics

11.2.4. Antidepressants

11.2.5. Antiepileptic agents

11.2.6. Anti-inflammatory agents

11.2.7. Antioxidants/free radical scavengers

11.2.8. Cytokines

11.2.9. Ion Channel Blockers

11.2.10. Neurosteroids

11.2.11. Nutraceuticals

11.2.12. Pathway Inhibitor

11.2.13. Others (Vaccines, Toxins, etc.)

11.3. Europe Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.3.1. Cerebrovascular Disease

11.3.1.1. ischemic stroke

11.3.1.2. hemorrhagic stroke

11.3.1.3. cerebrovascular anomalies

11.3.1.3.1. intracranial aneurysms

11.3.1.3.2. arteriovenous malformations

11.3.2. Neurodegenerative Disorders

11.3.2.1. Alzheimer’s Disease

11.3.2.2. Parkinson’s Disease

11.3.2.3. Amyotrophic Lateral Sclerosis

11.3.2.4. Progressive supranuclear palsy (PSP)

11.3.2.5. Corticobasal Degeneration (CBD)

11.3.2.6. Frontotemporal Dementia (FTD)

11.3.2.7. Dementia With Lewy Bodies (DLB)

11.3.2.8. Huntington’s Disease (HD)

11.3.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

11.3.3. Traumatic CNS Injuries

11.3.3.1. Coup-Contrecoup Brain Injury

11.3.3.2. Concussion

11.3.3.3. Brain Contusion

11.3.3.4. Diffuse Axonal Injury

11.3.3.5. Penetrating Injury

11.3.3.6. Second Impact Syndrome

11.3.3.7. Others

11.3.4. Others

11.4. Europe Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. France

11.4.1.1. France Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

11.4.1.1.1. Anesthetics

11.4.1.1.2. Antagonists

11.4.1.1.3. Antibiotics

11.4.1.1.4. Antidepressants

11.4.1.1.5. Antiepileptic agents

11.4.1.1.6. Anti-inflammatory agents

11.4.1.1.7. Antioxidants/free radical scavengers

11.4.1.1.8. Cytokines

11.4.1.1.9. Ion Channel Blockers

11.4.1.1.10. Neurosteroids

11.4.1.1.11. Nutraceuticals

11.4.1.1.12. Pathway Inhibitor

11.4.1.1.13. Others (Vaccines, Toxins, etc.)

11.4.1.2. France Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.1.2.1. Cerebrovascular Disease

11.4.1.2.1.1. ischemic stroke

11.4.1.2.1.2. hemorrhagic stroke

11.4.1.2.1.3. cerebrovascular anomalies

11.4.1.2.1.3.1. intracranial aneurysms

11.4.1.2.1.3.2. arteriovenous malformations

11.4.1.2.2. Neurodegenerative Disorders

11.4.1.2.2.1. Alzheimer’s Disease

11.4.1.2.2.2. Parkinson’s Disease

11.4.1.2.2.3. Amyotrophic Lateral Sclerosis

11.4.1.2.2.4. Progressive supranuclear palsy (PSP)

11.4.1.2.2.5. Corticobasal Degeneration (CBD)

11.4.1.2.2.6. Frontotemporal Dementia (FTD)

11.4.1.2.2.7. Dementia With Lewy Bodies (DLB)

11.4.1.2.2.8. Huntington’s Disease (HD)

11.4.1.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

11.4.1.2.3. Traumatic CNS Injuries

11.4.1.2.3.1. Coup-Contrecoup Brain Injury

11.4.1.2.3.2. Concussion

11.4.1.2.3.3. Brain Contusion

11.4.1.2.3.4. Diffuse Axonal Injury

11.4.1.2.3.5. Penetrating Injury

11.4.1.2.3.6. Second Impact Syndrome

11.4.1.2.3.7. Others

11.4.1.2.4. Others

11.4.2. The UK

11.4.2.1. The UK Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

11.4.2.1.1. Anesthetics

11.4.2.1.2. Antagonists

11.4.2.1.3. Antibiotics

11.4.2.1.4. Antidepressants

11.4.2.1.5. Antiepileptic agents

11.4.2.1.6. Anti-inflammatory agents

11.4.2.1.7. Antioxidants/free radical scavengers

11.4.2.1.8. Cytokines

11.4.2.1.9. Ion Channel Blockers

11.4.2.1.10. Neurosteroids

11.4.2.1.11. Nutraceuticals

11.4.2.1.12. Pathway Inhibitor

11.4.2.1.13. Others (Vaccines, Toxins, etc.)

11.4.2.2. The UK Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.2.2.1. Cerebrovascular Disease

11.4.2.2.1.1. ischemic stroke

11.4.2.2.1.2. hemorrhagic stroke

11.4.2.2.1.3. cerebrovascular anomalies

11.4.2.2.1.3.1. intracranial aneurysms

11.4.2.2.1.3.2. arteriovenous malformations

11.4.2.2.2. Neurodegenerative Disorders

11.4.2.2.2.1. Alzheimer’s Disease

11.4.2.2.2.2. Parkinson’s Disease

11.4.2.2.2.3. Amyotrophic Lateral Sclerosis

11.4.2.2.2.4. Progressive supranuclear palsy (PSP)

11.4.2.2.2.5. Corticobasal Degeneration (CBD)

11.4.2.2.2.6. Frontotemporal Dementia (FTD)

11.4.2.2.2.7. Dementia With Lewy Bodies (DLB)

11.4.2.2.2.8. Huntington’s Disease (HD)

11.4.2.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

11.4.2.2.3. Traumatic CNS Injuries

11.4.2.2.3.1. Coup-Contrecoup Brain Injury

11.4.2.2.3.2. Concussion

11.4.2.2.3.3. Brain Contusion

11.4.2.2.3.4. Diffuse Axonal Injury

11.4.2.2.3.5. Penetrating Injury

11.4.2.2.3.6. Second Impact Syndrome

11.4.2.2.3.7. Others

11.4.2.2.4. Others

11.4.3. Spain

11.4.3.1. Spain Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

11.4.3.1.1. Anesthetics

11.4.3.1.2. Antagonists

11.4.3.1.3. Antibiotics

11.4.3.1.4. Antidepressants

11.4.3.1.5. Antiepileptic agents

11.4.3.1.6. Anti-inflammatory agents

11.4.3.1.7. Antioxidants/free radical scavengers

11.4.3.1.8. Cytokines

11.4.3.1.9. Ion Channel Blockers

11.4.3.1.10. Neurosteroids

11.4.3.1.11. Nutraceuticals

11.4.3.1.12. Pathway Inhibitor

11.4.3.1.13. Others (Vaccines, Toxins, etc.)

11.4.3.2. Spain Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.3.2.1. Cerebrovascular Disease

11.4.3.2.1.1. ischemic stroke

11.4.3.2.1.2. hemorrhagic stroke

11.4.3.2.1.3. cerebrovascular anomalies

11.4.3.2.1.3.1. intracranial aneurysms

11.4.3.2.1.3.2. arteriovenous malformations

11.4.3.2.2. Neurodegenerative Disorders

11.4.3.2.2.1. Alzheimer’s Disease

11.4.3.2.2.2. Parkinson’s Disease

11.4.3.2.2.3. Amyotrophic Lateral Sclerosis

11.4.3.2.2.4. Progressive supranuclear palsy (PSP)

11.4.3.2.2.5. Corticobasal Degeneration (CBD)

11.4.3.2.2.6. Frontotemporal Dementia (FTD)

11.4.3.2.2.7. Dementia With Lewy Bodies (DLB)

11.4.3.2.2.8. Huntington’s Disease (HD)

11.4.3.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

11.4.3.2.3. Traumatic CNS Injuries

11.4.3.2.3.1. Coup-Contrecoup Brain Injury

11.4.3.2.3.2. Concussion

11.4.3.2.3.3. Brain Contusion

11.4.3.2.3.4. Diffuse Axonal Injury

11.4.3.2.3.5. Penetrating Injury

11.4.3.2.3.6. Second Impact Syndrome

11.4.3.2.3.7. Others

11.4.3.2.4. Others

11.4.4. Germany

11.4.4.1. Germany Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

11.4.4.1.1. Anesthetics

11.4.4.1.2. Antagonists

11.4.4.1.3. Antibiotics

11.4.4.1.4. Antidepressants

11.4.4.1.5. Antiepileptic agents

11.4.4.1.6. Anti-inflammatory agents

11.4.4.1.7. Antioxidants/free radical scavengers

11.4.4.1.8. Cytokines

11.4.4.1.9. Ion Channel Blockers

11.4.4.1.10. Neurosteroids

11.4.4.1.11. Nutraceuticals

11.4.4.1.12. Pathway Inhibitor

11.4.4.1.13. Others (Vaccines, Toxins, etc.)

11.4.4.2. Germany Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.4.2.1. Cerebrovascular Disease

11.4.4.2.1.1. ischemic stroke

11.4.4.2.1.2. hemorrhagic stroke

11.4.4.2.1.3. cerebrovascular anomalies

11.4.4.2.1.3.1. intracranial aneurysms

11.4.4.2.1.3.2. arteriovenous malformations

11.4.4.2.2. Neurodegenerative Disorders

11.4.4.2.2.1. Alzheimer’s Disease

11.4.4.2.2.2. Parkinson’s Disease

11.4.4.2.2.3. Amyotrophic Lateral Sclerosis

11.4.4.2.2.4. Progressive supranuclear palsy (PSP)

11.4.4.2.2.5. Corticobasal Degeneration (CBD)

11.4.4.2.2.6. Frontotemporal Dementia (FTD)

11.4.4.2.2.7. Dementia With Lewy Bodies (DLB)

11.4.4.2.2.8. Huntington’s Disease (HD)

11.4.4.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

11.4.4.2.3. Traumatic CNS Injuries

11.4.4.2.3.1. Coup-Contrecoup Brain Injury

11.4.4.2.3.2. Concussion

11.4.4.2.3.3. Brain Contusion

11.4.4.2.3.4. Diffuse Axonal Injury

11.4.4.2.3.5. Penetrating Injury

11.4.4.2.3.6. Second Impact Syndrome

11.4.4.2.3.7. Others

11.4.4.2.4. Others

11.4.5. Italy

11.4.5.1. Italy Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

11.4.5.1.1. Anesthetics

11.4.5.1.2. Antagonists

11.4.5.1.3. Antibiotics

11.4.5.1.4. Antidepressants

11.4.5.1.5. Antiepileptic agents

11.4.5.1.6. Anti-inflammatory agents

11.4.5.1.7. Antioxidants/free radical scavengers

11.4.5.1.8. Cytokines

11.4.5.1.9. Ion Channel Blockers

11.4.5.1.10. Neurosteroids

11.4.5.1.11. Nutraceuticals

11.4.5.1.12. Pathway Inhibitor

11.4.5.1.13. Others (Vaccines, Toxins, etc.)

11.4.5.2. Italy Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.5.2.1. Cerebrovascular Disease

11.4.5.2.1.1. ischemic stroke

11.4.5.2.1.2. hemorrhagic stroke

11.4.5.2.1.3. cerebrovascular anomalies

11.4.5.2.1.3.1. intracranial aneurysms

11.4.5.2.1.3.2. arteriovenous malformations

11.4.5.2.2. Neurodegenerative Disorders

11.4.5.2.2.1. Alzheimer’s Disease

11.4.5.2.2.2. Parkinson’s Disease

11.4.5.2.2.3. Amyotrophic Lateral Sclerosis

11.4.5.2.2.4. Progressive supranuclear palsy (PSP)

11.4.5.2.2.5. Corticobasal Degeneration (CBD)

11.4.5.2.2.6. Frontotemporal Dementia (FTD)

11.4.5.2.2.7. Dementia With Lewy Bodies (DLB)

11.4.5.2.2.8. Huntington’s Disease (HD)

11.4.5.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

11.4.5.2.3. Traumatic CNS Injuries

11.4.5.2.3.1. Coup-Contrecoup Brain Injury

11.4.5.2.3.2. Concussion

11.4.5.2.3.3. Brain Contusion

11.4.5.2.3.4. Diffuse Axonal Injury

11.4.5.2.3.5. Penetrating Injury

11.4.5.2.3.6. Second Impact Syndrome

11.4.5.2.3.7. Others

11.4.5.2.4. Others

11.4.6. Nordic Countries

11.4.6.1. Nordic Countries Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

11.4.6.1.1. Anesthetics

11.4.6.1.2. Antagonists

11.4.6.1.3. Antibiotics

11.4.6.1.4. Antidepressants

11.4.6.1.5. Antiepileptic agents

11.4.6.1.6. Anti-inflammatory agents

11.4.6.1.7. Antioxidants/free radical scavengers

11.4.6.1.8. Cytokines

11.4.6.1.9. Ion Channel Blockers

11.4.6.1.10. Neurosteroids

11.4.6.1.11. Nutraceuticals

11.4.6.1.12. Pathway Inhibitor

11.4.6.1.13. Others (Vaccines, Toxins, etc.)

11.4.6.2. Nordic Countries Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.6.2.1. Cerebrovascular Disease

11.4.6.2.1.1. ischemic stroke

11.4.6.2.1.2. hemorrhagic stroke

11.4.6.2.1.3. cerebrovascular anomalies

11.4.6.2.1.3.1. intracranial aneurysms

11.4.6.2.1.3.2. arteriovenous malformations

11.4.6.2.2. Neurodegenerative Disorders

11.4.6.2.2.1. Alzheimer’s Disease

11.4.6.2.2.2. Parkinson’s Disease

11.4.6.2.2.3. Amyotrophic Lateral Sclerosis

11.4.6.2.2.4. Progressive supranuclear palsy (PSP)

11.4.6.2.2.5. Corticobasal Degeneration (CBD)

11.4.6.2.2.6. Frontotemporal Dementia (FTD)

11.4.6.2.2.7. Dementia With Lewy Bodies (DLB)

11.4.6.2.2.8. Huntington’s Disease (HD)

11.4.6.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

11.4.6.2.3. Traumatic CNS Injuries

11.4.6.2.3.1. Coup-Contrecoup Brain Injury

11.4.6.2.3.2. Concussion

11.4.6.2.3.3. Brain Contusion

11.4.6.2.3.4. Diffuse Axonal Injury

11.4.6.2.3.5. Penetrating Injury

11.4.6.2.3.6. Second Impact Syndrome

11.4.6.2.3.7. Others

11.4.6.2.4. Others

11.4.6.3. Nordic Countries Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country

11.4.6.3.1. Denmark

11.4.6.3.2. Finland

11.4.6.3.3. Iceland

11.4.6.3.4. Sweden

11.4.6.3.5. Norway

11.4.7. Benelux Union

11.4.7.1. Benelux Union Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

11.4.7.1.1. Anesthetics

11.4.7.1.2. Antagonists

11.4.7.1.3. Antibiotics

11.4.7.1.4. Antidepressants

11.4.7.1.5. Antiepileptic agents

11.4.7.1.6. Anti-inflammatory agents

11.4.7.1.7. Antioxidants/free radical scavengers

11.4.7.1.8. Cytokines

11.4.7.1.9. Ion Channel Blockers

11.4.7.1.10. Neurosteroids

11.4.7.1.11. Nutraceuticals

11.4.7.1.12. Pathway Inhibitor

11.4.7.1.13. Others (Vaccines, Toxins, etc.)

11.4.7.2. Benelux Union Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.7.2.1. Cerebrovascular Disease

11.4.7.2.1.1. ischemic stroke

11.4.7.2.1.2. hemorrhagic stroke

11.4.7.2.1.3. cerebrovascular anomalies

11.4.7.2.1.3.1. intracranial aneurysms

11.4.7.2.1.3.2. arteriovenous malformations

11.4.7.2.2. Neurodegenerative Disorders

11.4.7.2.2.1. Alzheimer’s Disease

11.4.7.2.2.2. Parkinson’s Disease

11.4.7.2.2.3. Amyotrophic Lateral Sclerosis

11.4.7.2.2.4. Progressive supranuclear palsy (PSP)

11.4.7.2.2.5. Corticobasal Degeneration (CBD)

11.4.7.2.2.6. Frontotemporal Dementia (FTD)

11.4.7.2.2.7. Dementia With Lewy Bodies (DLB)

11.4.7.2.2.8. Huntington’s Disease (HD)

11.4.7.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

11.4.7.2.3. Traumatic CNS Injuries

11.4.7.2.3.1. Coup-Contrecoup Brain Injury

11.4.7.2.3.2. Concussion

11.4.7.2.3.3. Brain Contusion

11.4.7.2.3.4. Diffuse Axonal Injury

11.4.7.2.3.5. Penetrating Injury

11.4.7.2.3.6. Second Impact Syndrome

11.4.7.2.3.7. Others

11.4.7.2.4. Others

11.4.7.3. Benelux Union Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country

11.4.7.3.1. Belgium

11.4.7.3.2. The Netherlands

11.4.7.3.3. Luxembourg

11.4.8. Rest of Europe

11.4.8.1. Rest of Europe Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

11.4.8.1.1. Anesthetics

11.4.8.1.2. Antagonists

11.4.8.1.3. Antibiotics

11.4.8.1.4. Antidepressants

11.4.8.1.5. Antiepileptic agents

11.4.8.1.6. Anti-inflammatory agents

11.4.8.1.7. Antioxidants/free radical scavengers

11.4.8.1.8. Cytokines

11.4.8.1.9. Ion Channel Blockers

11.4.8.1.10. Neurosteroids

11.4.8.1.11. Nutraceuticals

11.4.8.1.12. Pathway Inhibitor

11.4.8.1.13. Others (Vaccines, Toxins, etc.)

11.4.8.2. Rest of Europe Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.8.2.1. Cerebrovascular Disease

11.4.8.2.1.1. ischemic stroke

11.4.8.2.1.2. hemorrhagic stroke

11.4.8.2.1.3. cerebrovascular anomalies

11.4.8.2.1.3.1. intracranial aneurysms

11.4.8.2.1.3.2. arteriovenous malformations

11.4.8.2.2. Neurodegenerative Disorders

11.4.8.2.2.1. Alzheimer’s Disease

11.4.8.2.2.2. Parkinson’s Disease

11.4.8.2.2.3. Amyotrophic Lateral Sclerosis

11.4.8.2.2.4. Progressive supranuclear palsy (PSP)

11.4.8.2.2.5. Corticobasal Degeneration (CBD)

11.4.8.2.2.6. Frontotemporal Dementia (FTD)

11.4.8.2.2.7. Dementia With Lewy Bodies (DLB)

11.4.8.2.2.8. Huntington’s Disease (HD)

11.4.8.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

11.4.8.2.3. Traumatic CNS Injuries

11.4.8.2.3.1. Coup-Contrecoup Brain Injury

11.4.8.2.3.2. Concussion

11.4.8.2.3.3. Brain Contusion

11.4.8.2.3.4. Diffuse Axonal Injury

11.4.8.2.3.5. Penetrating Injury

11.4.8.2.3.6. Second Impact Syndrome

11.4.8.2.3.7. Others

11.4.8.2.4. Others

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Drugs Type

11.5.3. By Application

12. Asia Pacific Neuroprotection Drugs Market Analysis and Forecasts, 2019 - 2027

12.1. Overview

12.1.1. Asia Pacific Neuroprotection Drugs Market Revenue (US$ Mn)

12.2. Asia Pacific Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

12.2.1. Anesthetics

12.2.2. Antagonists

12.2.3. Antibiotics

12.2.4. Antidepressants

12.2.5. Antiepileptic agents

12.2.6. Anti-inflammatory agents

12.2.7. Antioxidants/free radical scavengers

12.2.8. Cytokines

12.2.9. Ion Channel Blockers

12.2.10. Neurosteroids

12.2.11. Nutraceuticals

12.2.12. Pathway Inhibitor

12.2.13. Others (Vaccines, Toxins, etc.)

12.3. Asia Pacific Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.3.1. Cerebrovascular Disease

12.3.1.1. ischemic stroke

12.3.1.2. hemorrhagic stroke

12.3.1.3. cerebrovascular anomalies

12.3.1.3.1. intracranial aneurysms

12.3.1.3.2. arteriovenous malformations

12.3.2. Neurodegenerative Disorders

12.3.2.1. Alzheimer’s Disease

12.3.2.2. Parkinson’s Disease

12.3.2.3. Amyotrophic Lateral Sclerosis

12.3.2.4. Progressive supranuclear palsy (PSP)

12.3.2.5. Corticobasal Degeneration (CBD)

12.3.2.6. Frontotemporal Dementia (FTD)

12.3.2.7. Dementia With Lewy Bodies (DLB)

12.3.2.8. Huntington’s Disease (HD)

12.3.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

12.3.3. Traumatic CNS Injuries

12.3.3.1. Coup-Contrecoup Brain Injury

12.3.3.2. Concussion

12.3.3.3. Brain Contusion

12.3.3.4. Diffuse Axonal Injury

12.3.3.5. Penetrating Injury

12.3.3.6. Second Impact Syndrome

12.3.3.7. Others

12.3.4. Others

12.4. Asia Pacific Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country

12.4.1. China

12.4.1.1. China Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

12.4.1.1.1. Anesthetics

12.4.1.1.2. Antagonists

12.4.1.1.3. Antibiotics

12.4.1.1.4. Antidepressants

12.4.1.1.5. Antiepileptic agents

12.4.1.1.6. Anti-inflammatory agents

12.4.1.1.7. Antioxidants/free radical scavengers

12.4.1.1.8. Cytokines

12.4.1.1.9. Ion Channel Blockers

12.4.1.1.10. Neurosteroids

12.4.1.1.11. Nutraceuticals

12.4.1.1.12. Pathway Inhibitor

12.4.1.1.13. Others (Vaccines, Toxins, etc.)

12.4.1.2. China Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.1.2.1. Cerebrovascular Disease

12.4.1.2.1.1. ischemic stroke

12.4.1.2.1.2. hemorrhagic stroke

12.4.1.2.1.3. cerebrovascular anomalies

12.4.1.2.1.3.1. intracranial aneurysms

12.4.1.2.1.3.2. arteriovenous malformations

12.4.1.2.2. Neurodegenerative Disorders

12.4.1.2.2.1. Alzheimer’s Disease

12.4.1.2.2.2. Parkinson’s Disease

12.4.1.2.2.3. Amyotrophic Lateral Sclerosis

12.4.1.2.2.4. Progressive supranuclear palsy (PSP)

12.4.1.2.2.5. Corticobasal Degeneration (CBD)

12.4.1.2.2.6. Frontotemporal Dementia (FTD)

12.4.1.2.2.7. Dementia With Lewy Bodies (DLB)

12.4.1.2.2.8. Huntington’s Disease (HD)

12.4.1.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

12.4.1.2.3. Traumatic CNS Injuries

12.4.1.2.3.1. Coup-Contrecoup Brain Injury

12.4.1.2.3.2. Concussion

12.4.1.2.3.3. Brain Contusion

12.4.1.2.3.4. Diffuse Axonal Injury

12.4.1.2.3.5. Penetrating Injury

12.4.1.2.3.6. Second Impact Syndrome

12.4.1.2.3.7. Others

12.4.1.2.4. Others

12.4.2. Japan

12.4.2.1. Japan Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

12.4.2.1.1. Anesthetics

12.4.2.1.2. Antagonists

12.4.2.1.3. Antibiotics

12.4.2.1.4. Antidepressants

12.4.2.1.5. Antiepileptic agents

12.4.2.1.6. Anti-inflammatory agents

12.4.2.1.7. Antioxidants/free radical scavengers

12.4.2.1.8. Cytokines

12.4.2.1.9. Ion Channel Blockers

12.4.2.1.10. Neurosteroids

12.4.2.1.11. Nutraceuticals

12.4.2.1.12. Pathway Inhibitor

12.4.2.1.13. Others (Vaccines, Toxins, etc.)

12.4.2.2. Japan Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.2.2.1. Cerebrovascular Disease

12.4.2.2.1.1. ischemic stroke

12.4.2.2.1.2. hemorrhagic stroke

12.4.2.2.1.3. cerebrovascular anomalies

12.4.2.2.1.3.1. intracranial aneurysms

12.4.2.2.1.3.2. arteriovenous malformations

12.4.2.2.2. Neurodegenerative Disorders

12.4.2.2.2.1. Alzheimer’s Disease

12.4.2.2.2.2. Parkinson’s Disease

12.4.2.2.2.3. Amyotrophic Lateral Sclerosis

12.4.2.2.2.4. Progressive supranuclear palsy (PSP)

12.4.2.2.2.5. Corticobasal Degeneration (CBD)

12.4.2.2.2.6. Frontotemporal Dementia (FTD)

12.4.2.2.2.7. Dementia With Lewy Bodies (DLB)

12.4.2.2.2.8. Huntington’s Disease (HD)

12.4.2.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

12.4.2.2.3. Traumatic CNS Injuries

12.4.2.2.3.1. Coup-Contrecoup Brain Injury

12.4.2.2.3.2. Concussion

12.4.2.2.3.3. Brain Contusion

12.4.2.2.3.4. Diffuse Axonal Injury

12.4.2.2.3.5. Penetrating Injury

12.4.2.2.3.6. Second Impact Syndrome

12.4.2.2.3.7. Others

12.4.2.2.4. Others

12.4.3. India

12.4.3.1. India Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

12.4.3.1.1. Anesthetics

12.4.3.1.2. Antagonists

12.4.3.1.3. Antibiotics

12.4.3.1.4. Antidepressants

12.4.3.1.5. Antiepileptic agents

12.4.3.1.6. Anti-inflammatory agents

12.4.3.1.7. Antioxidants/free radical scavengers

12.4.3.1.8. Cytokines

12.4.3.1.9. Ion Channel Blockers

12.4.3.1.10. Neurosteroids

12.4.3.1.11. Nutraceuticals

12.4.3.1.12. Pathway Inhibitor

12.4.3.1.13. Others (Vaccines, Toxins, etc.)

12.4.3.2. India Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.3.2.1. Cerebrovascular Disease

12.4.3.2.1.1. ischemic stroke

12.4.3.2.1.2. hemorrhagic stroke

12.4.3.2.1.3. cerebrovascular anomalies

12.4.3.2.1.3.1. intracranial aneurysms

12.4.3.2.1.3.2. arteriovenous malformations

12.4.3.2.2. Neurodegenerative Disorders

12.4.3.2.2.1. Alzheimer’s Disease

12.4.3.2.2.2. Parkinson’s Disease

12.4.3.2.2.3. Amyotrophic Lateral Sclerosis

12.4.3.2.2.4. Progressive supranuclear palsy (PSP)

12.4.3.2.2.5. Corticobasal Degeneration (CBD)

12.4.3.2.2.6. Frontotemporal Dementia (FTD)

12.4.3.2.2.7. Dementia With Lewy Bodies (DLB)

12.4.3.2.2.8. Huntington’s Disease (HD)

12.4.3.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

12.4.3.2.3. Traumatic CNS Injuries

12.4.3.2.3.1. Coup-Contrecoup Brain Injury

12.4.3.2.3.2. Concussion

12.4.3.2.3.3. Brain Contusion

12.4.3.2.3.4. Diffuse Axonal Injury

12.4.3.2.3.5. Penetrating Injury

12.4.3.2.3.6. Second Impact Syndrome

12.4.3.2.3.7. Others

12.4.3.2.4. Others

12.4.4. New Zealand

12.4.4.1. New Zealand Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

12.4.4.1.1. Anesthetics

12.4.4.1.2. Antagonists

12.4.4.1.3. Antibiotics

12.4.4.1.4. Antidepressants

12.4.4.1.5. Antiepileptic agents

12.4.4.1.6. Anti-inflammatory agents

12.4.4.1.7. Antioxidants/free radical scavengers

12.4.4.1.8. Cytokines

12.4.4.1.9. Ion Channel Blockers

12.4.4.1.10. Neurosteroids

12.4.4.1.11. Nutraceuticals

12.4.4.1.12. Pathway Inhibitor

12.4.4.1.13. Others (Vaccines, Toxins, etc.)

12.4.4.2. New Zealand Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.4.2.1. Cerebrovascular Disease

12.4.4.2.1.1. ischemic stroke

12.4.4.2.1.2. hemorrhagic stroke

12.4.4.2.1.3. cerebrovascular anomalies

12.4.4.2.1.3.1. intracranial aneurysms

12.4.4.2.1.3.2. arteriovenous malformations

12.4.4.2.2. Neurodegenerative Disorders

12.4.4.2.2.1. Alzheimer’s Disease

12.4.4.2.2.2. Parkinson’s Disease

12.4.4.2.2.3. Amyotrophic Lateral Sclerosis

12.4.4.2.2.4. Progressive supranuclear palsy (PSP)

12.4.4.2.2.5. Corticobasal Degeneration (CBD)

12.4.4.2.2.6. Frontotemporal Dementia (FTD)

12.4.4.2.2.7. Dementia With Lewy Bodies (DLB)

12.4.4.2.2.8. Huntington’s Disease (HD)

12.4.4.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

12.4.4.2.3. Traumatic CNS Injuries

12.4.4.2.3.1. Coup-Contrecoup Brain Injury

12.4.4.2.3.2. Concussion

12.4.4.2.3.3. Brain Contusion

12.4.4.2.3.4. Diffuse Axonal Injury

12.4.4.2.3.5. Penetrating Injury

12.4.4.2.3.6. Second Impact Syndrome

12.4.4.2.3.7. Others

12.4.4.2.4. Others

12.4.5. Australia

12.4.5.1. Australia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

12.4.5.1.1. Anesthetics

12.4.5.1.2. Antagonists

12.4.5.1.3. Antibiotics

12.4.5.1.4. Antidepressants

12.4.5.1.5. Antiepileptic agents

12.4.5.1.6. Anti-inflammatory agents

12.4.5.1.7. Antioxidants/free radical scavengers

12.4.5.1.8. Cytokines

12.4.5.1.9. Ion Channel Blockers

12.4.5.1.10. Neurosteroids

12.4.5.1.11. Nutraceuticals

12.4.5.1.12. Pathway Inhibitor

12.4.5.1.13. Others (Vaccines, Toxins, etc.)

12.4.5.2. Australia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.5.2.1. Cerebrovascular Disease

12.4.5.2.1.1. ischemic stroke

12.4.5.2.1.2. hemorrhagic stroke

12.4.5.2.1.3. cerebrovascular anomalies

12.4.5.2.1.3.1. intracranial aneurysms

12.4.5.2.1.3.2. arteriovenous malformations

12.4.5.2.2. Neurodegenerative Disorders

12.4.5.2.2.1. Alzheimer’s Disease

12.4.5.2.2.2. Parkinson’s Disease

12.4.5.2.2.3. Amyotrophic Lateral Sclerosis

12.4.5.2.2.4. Progressive supranuclear palsy (PSP)

12.4.5.2.2.5. Corticobasal Degeneration (CBD)

12.4.5.2.2.6. Frontotemporal Dementia (FTD)

12.4.5.2.2.7. Dementia With Lewy Bodies (DLB)

12.4.5.2.2.8. Huntington’s Disease (HD)

12.4.5.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

12.4.5.2.3. Traumatic CNS Injuries

12.4.5.2.3.1. Coup-Contrecoup Brain Injury

12.4.5.2.3.2. Concussion

12.4.5.2.3.3. Brain Contusion

12.4.5.2.3.4. Diffuse Axonal Injury

12.4.5.2.3.5. Penetrating Injury

12.4.5.2.3.6. Second Impact Syndrome

12.4.5.2.3.7. Others

12.4.5.2.4. Others

12.4.6. South Korea

12.4.6.1. South Korea Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

12.4.6.1.1. Anesthetics

12.4.6.1.2. Antagonists

12.4.6.1.3. Antibiotics

12.4.6.1.4. Antidepressants

12.4.6.1.5. Antiepileptic agents

12.4.6.1.6. Anti-inflammatory agents

12.4.6.1.7. Antioxidants/free radical scavengers

12.4.6.1.8. Cytokines

12.4.6.1.9. Ion Channel Blockers

12.4.6.1.10. Neurosteroids

12.4.6.1.11. Nutraceuticals

12.4.6.1.12. Pathway Inhibitor

12.4.6.1.13. Others (Vaccines, Toxins, etc.)

12.4.6.2. South Korea Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.6.2.1. Cerebrovascular Disease

12.4.6.2.1.1. ischemic stroke

12.4.6.2.1.2. hemorrhagic stroke

12.4.6.2.1.3. cerebrovascular anomalies

12.4.6.2.1.3.1. intracranial aneurysms

12.4.6.2.1.3.2. arteriovenous malformations

12.4.6.2.2. Neurodegenerative Disorders

12.4.6.2.2.1. Alzheimer’s Disease

12.4.6.2.2.2. Parkinson’s Disease

12.4.6.2.2.3. Amyotrophic Lateral Sclerosis

12.4.6.2.2.4. Progressive supranuclear palsy (PSP)

12.4.6.2.2.5. Corticobasal Degeneration (CBD)

12.4.6.2.2.6. Frontotemporal Dementia (FTD)

12.4.6.2.2.7. Dementia With Lewy Bodies (DLB)

12.4.6.2.2.8. Huntington’s Disease (HD)

12.4.6.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

12.4.6.2.3. Traumatic CNS Injuries

12.4.6.2.3.1. Coup-Contrecoup Brain Injury

12.4.6.2.3.2. Concussion

12.4.6.2.3.3. Brain Contusion

12.4.6.2.3.4. Diffuse Axonal Injury

12.4.6.2.3.5. Penetrating Injury

12.4.6.2.3.6. Second Impact Syndrome

12.4.6.2.3.7. Others

12.4.6.2.4. Others

12.4.7. Southeast Asia

12.4.7.1. Southeast Asia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

12.4.7.1.1. Anesthetics

12.4.7.1.2. Antagonists

12.4.7.1.3. Antibiotics

12.4.7.1.4. Antidepressants

12.4.7.1.5. Antiepileptic agents

12.4.7.1.6. Anti-inflammatory agents

12.4.7.1.7. Antioxidants/free radical scavengers

12.4.7.1.8. Cytokines

12.4.7.1.9. Ion Channel Blockers

12.4.7.1.10. Neurosteroids

12.4.7.1.11. Nutraceuticals

12.4.7.1.12. Pathway Inhibitor

12.4.7.1.13. Others (Vaccines, Toxins, etc.)

12.4.7.2. Southeast Asia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.7.2.1. Cerebrovascular Disease

12.4.7.2.1.1. ischemic stroke

12.4.7.2.1.2. hemorrhagic stroke

12.4.7.2.1.3. cerebrovascular anomalies

12.4.7.2.1.3.1. intracranial aneurysms

12.4.7.2.1.3.2. arteriovenous malformations

12.4.7.2.2. Neurodegenerative Disorders

12.4.7.2.2.1. Alzheimer’s Disease

12.4.7.2.2.2. Parkinson’s Disease

12.4.7.2.2.3. Amyotrophic Lateral Sclerosis

12.4.7.2.2.4. Progressive supranuclear palsy (PSP)

12.4.7.2.2.5. Corticobasal Degeneration (CBD)

12.4.7.2.2.6. Frontotemporal Dementia (FTD)

12.4.7.2.2.7. Dementia With Lewy Bodies (DLB)

12.4.7.2.2.8. Huntington’s Disease (HD)

12.4.7.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

12.4.7.2.3. Traumatic CNS Injuries

12.4.7.2.3.1. Coup-Contrecoup Brain Injury

12.4.7.2.3.2. Concussion

12.4.7.2.3.3. Brain Contusion

12.4.7.2.3.4. Diffuse Axonal Injury

12.4.7.2.3.5. Penetrating Injury

12.4.7.2.3.6. Second Impact Syndrome

12.4.7.2.3.7. Others

12.4.7.2.4. Others

12.4.7.3. Southeast Asia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country

12.4.7.3.1. Indonesia

12.4.7.3.2. Thailand

12.4.7.3.3. Malaysia

12.4.7.3.4. Singapore

12.4.7.3.5. Rest of Southeast Asia

12.4.8. Rest of Asia Pacific

12.4.8.1. Rest of Asia Pacific Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

12.4.8.1.1. Anesthetics

12.4.8.1.2. Antagonists

12.4.8.1.3. Antibiotics

12.4.8.1.4. Antidepressants

12.4.8.1.5. Antiepileptic agents

12.4.8.1.6. Anti-inflammatory agents

12.4.8.1.7. Antioxidants/free radical scavengers

12.4.8.1.8. Cytokines

12.4.8.1.9. Ion Channel Blockers

12.4.8.1.10. Neurosteroids

12.4.8.1.11. Nutraceuticals

12.4.8.1.12. Pathway Inhibitor

12.4.8.1.13. Others (Vaccines, Toxins, etc.)

12.4.8.2. Rest of Asia Pacific Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.8.2.1. Cerebrovascular Disease

12.4.8.2.1.1. ischemic stroke

12.4.8.2.1.2. hemorrhagic stroke

12.4.8.2.1.3. cerebrovascular anomalies

12.4.8.2.1.3.1. intracranial aneurysms

12.4.8.2.1.3.2. arteriovenous malformations

12.4.8.2.2. Neurodegenerative Disorders

12.4.8.2.2.1. Alzheimer’s Disease

12.4.8.2.2.2. Parkinson’s Disease

12.4.8.2.2.3. Amyotrophic Lateral Sclerosis

12.4.8.2.2.4. Progressive supranuclear palsy (PSP)

12.4.8.2.2.5. Corticobasal Degeneration (CBD)

12.4.8.2.2.6. Frontotemporal Dementia (FTD)

12.4.8.2.2.7. Dementia With Lewy Bodies (DLB)

12.4.8.2.2.8. Huntington’s Disease (HD)

12.4.8.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

12.4.8.2.3. Traumatic CNS Injuries

12.4.8.2.3.1. Coup-Contrecoup Brain Injury

12.4.8.2.3.2. Concussion

12.4.8.2.3.3. Brain Contusion

12.4.8.2.3.4. Diffuse Axonal Injury

12.4.8.2.3.5. Penetrating Injury

12.4.8.2.3.6. Second Impact Syndrome

12.4.8.2.3.7. Others

12.4.8.2.4. Others

12.5. Key Segment for Channeling Investments

12.5.1. By Country

12.5.2. By Drugs Type

12.5.3. By Application

13. Middle East and Africa Neuroprotection Drugs Market Analysis and Forecasts, 2019 - 2027

13.1. Overview

13.1.1. Middle East and Africa Neuroprotection Drugs Market Revenue (US$ Mn)

13.2. Middle East and Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

13.2.1. Anesthetics

13.2.2. Antagonists

13.2.3. Antibiotics

13.2.4. Antidepressants

13.2.5. Antiepileptic agents

13.2.6. Anti-inflammatory agents

13.2.7. Antioxidants/free radical scavengers

13.2.8. Cytokines

13.2.9. Ion Channel Blockers

13.2.10. Neurosteroids

13.2.11. Nutraceuticals

13.2.12. Pathway Inhibitor

13.2.13. Others (Vaccines, Toxins, etc.)

13.3. Middle East and Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.3.1. Cerebrovascular Disease

13.3.1.1. ischemic stroke

13.3.1.2. hemorrhagic stroke

13.3.1.3. cerebrovascular anomalies

13.3.1.3.1. intracranial aneurysms

13.3.1.3.2. arteriovenous malformations

13.3.2. Neurodegenerative Disorders

13.3.2.1. Alzheimer’s Disease

13.3.2.2. Parkinson’s Disease

13.3.2.3. Amyotrophic Lateral Sclerosis

13.3.2.4. Progressive supranuclear palsy (PSP)

13.3.2.5. Corticobasal Degeneration (CBD)

13.3.2.6. Frontotemporal Dementia (FTD)

13.3.2.7. Dementia With Lewy Bodies (DLB)

13.3.2.8. Huntington’s Disease (HD)

13.3.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

13.3.3. Traumatic CNS Injuries

13.3.3.1. Coup-Contrecoup Brain Injury

13.3.3.2. Concussion

13.3.3.3. Brain Contusion

13.3.3.4. Diffuse Axonal Injury

13.3.3.5. Penetrating Injury

13.3.3.6. Second Impact Syndrome

13.3.3.7. Others

13.3.4. Others

13.4. Middle East and Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country

13.4.1. Saudi Arabia

13.4.1.1. Saudi Arabia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

13.4.1.1.1. Anesthetics

13.4.1.1.2. Antagonists

13.4.1.1.3. Antibiotics

13.4.1.1.4. Antidepressants

13.4.1.1.5. Antiepileptic agents

13.4.1.1.6. Anti-inflammatory agents

13.4.1.1.7. Antioxidants/free radical scavengers

13.4.1.1.8. Cytokines

13.4.1.1.9. Ion Channel Blockers

13.4.1.1.10. Neurosteroids

13.4.1.1.11. Nutraceuticals

13.4.1.1.12. Pathway Inhibitor

13.4.1.1.13. Others (Vaccines, Toxins, etc.)

13.4.1.2. Saudi Arabia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.1.2.1. Cerebrovascular Disease

13.4.1.2.1.1. ischemic stroke

13.4.1.2.1.2. hemorrhagic stroke

13.4.1.2.1.3. cerebrovascular anomalies

13.4.1.2.1.3.1. intracranial aneurysms

13.4.1.2.1.3.2. arteriovenous malformations

13.4.1.2.2. Neurodegenerative Disorders

13.4.1.2.2.1. Alzheimer’s Disease

13.4.1.2.2.2. Parkinson’s Disease

13.4.1.2.2.3. Amyotrophic Lateral Sclerosis

13.4.1.2.2.4. Progressive supranuclear palsy (PSP)

13.4.1.2.2.5. Corticobasal Degeneration (CBD)

13.4.1.2.2.6. Frontotemporal Dementia (FTD)

13.4.1.2.2.7. Dementia With Lewy Bodies (DLB)

13.4.1.2.2.8. Huntington’s Disease (HD)

13.4.1.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

13.4.1.2.3. Traumatic CNS Injuries

13.4.1.2.3.1. Coup-Contrecoup Brain Injury

13.4.1.2.3.2. Concussion

13.4.1.2.3.3. Brain Contusion

13.4.1.2.3.4. Diffuse Axonal Injury

13.4.1.2.3.5. Penetrating Injury

13.4.1.2.3.6. Second Impact Syndrome

13.4.1.2.3.7. Others

13.4.1.2.4. Others

13.4.2. UAE

13.4.2.1. UAE Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

13.4.2.1.1. Anesthetics

13.4.2.1.2. Antagonists

13.4.2.1.3. Antibiotics

13.4.2.1.4. Antidepressants

13.4.2.1.5. Antiepileptic agents

13.4.2.1.6. Anti-inflammatory agents

13.4.2.1.7. Antioxidants/free radical scavengers

13.4.2.1.8. Cytokines

13.4.2.1.9. Ion Channel Blockers

13.4.2.1.10. Neurosteroids

13.4.2.1.11. Nutraceuticals

13.4.2.1.12. Pathway Inhibitor

13.4.2.1.13. Others (Vaccines, Toxins, etc.)

13.4.2.2. UAE Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.2.2.1. Cerebrovascular Disease

13.4.2.2.1.1. ischemic stroke

13.4.2.2.1.2. hemorrhagic stroke

13.4.2.2.1.3. cerebrovascular anomalies

13.4.2.2.1.3.1. intracranial aneurysms

13.4.2.2.1.3.2. arteriovenous malformations

13.4.2.2.2. Neurodegenerative Disorders

13.4.2.2.2.1. Alzheimer’s Disease

13.4.2.2.2.2. Parkinson’s Disease

13.4.2.2.2.3. Amyotrophic Lateral Sclerosis

13.4.2.2.2.4. Progressive supranuclear palsy (PSP)

13.4.2.2.2.5. Corticobasal Degeneration (CBD)

13.4.2.2.2.6. Frontotemporal Dementia (FTD)

13.4.2.2.2.7. Dementia With Lewy Bodies (DLB)

13.4.2.2.2.8. Huntington’s Disease (HD)

13.4.2.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

13.4.2.2.3. Traumatic CNS Injuries

13.4.2.2.3.1. Coup-Contrecoup Brain Injury

13.4.2.2.3.2. Concussion

13.4.2.2.3.3. Brain Contusion

13.4.2.2.3.4. Diffuse Axonal Injury

13.4.2.2.3.5. Penetrating Injury

13.4.2.2.3.6. Second Impact Syndrome

13.4.2.2.3.7. Others

13.4.2.2.4. Others

13.4.3. Egypt

13.4.3.1. Egypt Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

13.4.3.1.1. Anesthetics

13.4.3.1.2. Antagonists

13.4.3.1.3. Antibiotics

13.4.3.1.4. Antidepressants

13.4.3.1.5. Antiepileptic agents

13.4.3.1.6. Anti-inflammatory agents

13.4.3.1.7. Antioxidants/free radical scavengers

13.4.3.1.8. Cytokines

13.4.3.1.9. Ion Channel Blockers

13.4.3.1.10. Neurosteroids

13.4.3.1.11. Nutraceuticals

13.4.3.1.12. Pathway Inhibitor

13.4.3.1.13. Others (Vaccines, Toxins, etc.)

13.4.3.2. Egypt Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.3.2.1. Cerebrovascular Disease

13.4.3.2.1.1. ischemic stroke

13.4.3.2.1.2. hemorrhagic stroke

13.4.3.2.1.3. cerebrovascular anomalies

13.4.3.2.1.3.1. intracranial aneurysms

13.4.3.2.1.3.2. arteriovenous malformations

13.4.3.2.2. Neurodegenerative Disorders

13.4.3.2.2.1. Alzheimer’s Disease

13.4.3.2.2.2. Parkinson’s Disease

13.4.3.2.2.3. Amyotrophic Lateral Sclerosis

13.4.3.2.2.4. Progressive supranuclear palsy (PSP)

13.4.3.2.2.5. Corticobasal Degeneration (CBD)

13.4.3.2.2.6. Frontotemporal Dementia (FTD)

13.4.3.2.2.7. Dementia With Lewy Bodies (DLB)

13.4.3.2.2.8. Huntington’s Disease (HD)

13.4.3.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

13.4.3.2.3. Traumatic CNS Injuries

13.4.3.2.3.1. Coup-Contrecoup Brain Injury

13.4.3.2.3.2. Concussion

13.4.3.2.3.3. Brain Contusion

13.4.3.2.3.4. Diffuse Axonal Injury

13.4.3.2.3.5. Penetrating Injury

13.4.3.2.3.6. Second Impact Syndrome

13.4.3.2.3.7. Others

13.4.3.2.4. Others

13.4.4. Kuwait

13.4.4.1. Kuwait Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

13.4.4.1.1. Anesthetics

13.4.4.1.2. Antagonists

13.4.4.1.3. Antibiotics

13.4.4.1.4. Antidepressants

13.4.4.1.5. Antiepileptic agents

13.4.4.1.6. Anti-inflammatory agents

13.4.4.1.7. Antioxidants/free radical scavengers

13.4.4.1.8. Cytokines

13.4.4.1.9. Ion Channel Blockers

13.4.4.1.10. Neurosteroids

13.4.4.1.11. Nutraceuticals

13.4.4.1.12. Pathway Inhibitor

13.4.4.1.13. Others (Vaccines, Toxins, etc.)

13.4.4.2. Kuwait Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.4.2.1. Cerebrovascular Disease

13.4.4.2.1.1. ischemic stroke

13.4.4.2.1.2. hemorrhagic stroke

13.4.4.2.1.3. cerebrovascular anomalies

13.4.4.2.1.3.1. intracranial aneurysms

13.4.4.2.1.3.2. arteriovenous malformations

13.4.4.2.2. Neurodegenerative Disorders

13.4.4.2.2.1. Alzheimer’s Disease

13.4.4.2.2.2. Parkinson’s Disease

13.4.4.2.2.3. Amyotrophic Lateral Sclerosis

13.4.4.2.2.4. Progressive supranuclear palsy (PSP)

13.4.4.2.2.5. Corticobasal Degeneration (CBD)

13.4.4.2.2.6. Frontotemporal Dementia (FTD)

13.4.4.2.2.7. Dementia With Lewy Bodies (DLB)

13.4.4.2.2.8. Huntington’s Disease (HD)

13.4.4.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

13.4.4.2.3. Traumatic CNS Injuries

13.4.4.2.3.1. Coup-Contrecoup Brain Injury

13.4.4.2.3.2. Concussion

13.4.4.2.3.3. Brain Contusion

13.4.4.2.3.4. Diffuse Axonal Injury

13.4.4.2.3.5. Penetrating Injury

13.4.4.2.3.6. Second Impact Syndrome

13.4.4.2.3.7. Others

13.4.4.2.4. Others

13.4.5. South Africa

13.4.5.1. South Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

13.4.5.1.1. Anesthetics

13.4.5.1.2. Antagonists

13.4.5.1.3. Antibiotics

13.4.5.1.4. Antidepressants

13.4.5.1.5. Antiepileptic agents

13.4.5.1.6. Anti-inflammatory agents

13.4.5.1.7. Antioxidants/free radical scavengers

13.4.5.1.8. Cytokines

13.4.5.1.9. Ion Channel Blockers

13.4.5.1.10. Neurosteroids

13.4.5.1.11. Nutraceuticals

13.4.5.1.12. Pathway Inhibitor

13.4.5.1.13. Others (Vaccines, Toxins, etc.)

13.4.5.2. South Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.5.2.1. Cerebrovascular Disease

13.4.5.2.1.1. ischemic stroke

13.4.5.2.1.2. hemorrhagic stroke

13.4.5.2.1.3. cerebrovascular anomalies

13.4.5.2.1.3.1. intracranial aneurysms

13.4.5.2.1.3.2. arteriovenous malformations

13.4.5.2.2. Neurodegenerative Disorders

13.4.5.2.2.1. Alzheimer’s Disease

13.4.5.2.2.2. Parkinson’s Disease

13.4.5.2.2.3. Amyotrophic Lateral Sclerosis

13.4.5.2.2.4. Progressive supranuclear palsy (PSP)

13.4.5.2.2.5. Corticobasal Degeneration (CBD)

13.4.5.2.2.6. Frontotemporal Dementia (FTD)

13.4.5.2.2.7. Dementia With Lewy Bodies (DLB)

13.4.5.2.2.8. Huntington’s Disease (HD)

13.4.5.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

13.4.5.2.3. Traumatic CNS Injuries

13.4.5.2.3.1. Coup-Contrecoup Brain Injury

13.4.5.2.3.2. Concussion

13.4.5.2.3.3. Brain Contusion

13.4.5.2.3.4. Diffuse Axonal Injury

13.4.5.2.3.5. Penetrating Injury

13.4.5.2.3.6. Second Impact Syndrome

13.4.5.2.3.7. Others

13.4.5.2.4. Others

13.4.6. Rest of Middle East & Africa

13.4.6.1. Rest of Middle East & Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

13.4.6.1.1. Anesthetics

13.4.6.1.2. Antagonists

13.4.6.1.3. Antibiotics

13.4.6.1.4. Antidepressants

13.4.6.1.5. Antiepileptic agents

13.4.6.1.6. Anti-inflammatory agents

13.4.6.1.7. Antioxidants/free radical scavengers

13.4.6.1.8. Cytokines

13.4.6.1.9. Ion Channel Blockers

13.4.6.1.10. Neurosteroids

13.4.6.1.11. Nutraceuticals

13.4.6.1.12. Pathway Inhibitor

13.4.6.1.13. Others (Vaccines, Toxins, etc.)

13.4.6.2. Rest of Middle East & Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.6.2.1. Cerebrovascular Disease

13.4.6.2.1.1. ischemic stroke

13.4.6.2.1.2. hemorrhagic stroke

13.4.6.2.1.3. cerebrovascular anomalies

13.4.6.2.1.3.1. intracranial aneurysms

13.4.6.2.1.3.2. arteriovenous malformations

13.4.6.2.2. Neurodegenerative Disorders

13.4.6.2.2.1. Alzheimer’s Disease

13.4.6.2.2.2. Parkinson’s Disease

13.4.6.2.2.3. Amyotrophic Lateral Sclerosis

13.4.6.2.2.4. Progressive supranuclear palsy (PSP)

13.4.6.2.2.5. Corticobasal Degeneration (CBD)

13.4.6.2.2.6. Frontotemporal Dementia (FTD)

13.4.6.2.2.7. Dementia With Lewy Bodies (DLB)

13.4.6.2.2.8. Huntington’s Disease (HD)

13.4.6.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

13.4.6.2.3. Traumatic CNS Injuries

13.4.6.2.3.1. Coup-Contrecoup Brain Injury

13.4.6.2.3.2. Concussion

13.4.6.2.3.3. Brain Contusion

13.4.6.2.3.4. Diffuse Axonal Injury

13.4.6.2.3.5. Penetrating Injury

13.4.6.2.3.6. Second Impact Syndrome

13.4.6.2.3.7. Others

13.4.6.2.4. Others

13.5. Key Segment for Channeling Investments

13.5.1. By Country

13.5.2. By Drugs Type

13.5.3. By Application

14. Latin America Neuroprotection Drugs Market Analysis and Forecasts, 2019 - 2027

14.1. Overview

14.1.1. Latin America Neuroprotection Drugs Market Revenue (US$ Mn)

14.2. Latin America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

14.2.1. Anesthetics

14.2.2. Antagonists

14.2.3. Antibiotics

14.2.4. Antidepressants

14.2.5. Antiepileptic agents

14.2.6. Anti-inflammatory agents

14.2.7. Antioxidants/free radical scavengers

14.2.8. Cytokines

14.2.9. Ion Channel Blockers

14.2.10. Neurosteroids

14.2.11. Nutraceuticals

14.2.12. Pathway Inhibitor

14.2.13. Others (Vaccines, Toxins, etc.)

14.3. Latin America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

14.3.1. Cerebrovascular Disease

14.3.1.1. ischemic stroke

14.3.1.2. hemorrhagic stroke

14.3.1.3. cerebrovascular anomalies

14.3.1.3.1. intracranial aneurysms

14.3.1.3.2. arteriovenous malformations

14.3.2. Neurodegenerative Disorders

14.3.2.1. Alzheimer’s Disease

14.3.2.2. Parkinson’s Disease

14.3.2.3. Amyotrophic Lateral Sclerosis

14.3.2.4. Progressive supranuclear palsy (PSP)

14.3.2.5. Corticobasal Degeneration (CBD)

14.3.2.6. Frontotemporal Dementia (FTD)

14.3.2.7. Dementia With Lewy Bodies (DLB)

14.3.2.8. Huntington’s Disease (HD)

14.3.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

14.3.3. Traumatic CNS Injuries

14.3.3.1. Coup-Contrecoup Brain Injury

14.3.3.2. Concussion

14.3.3.3. Brain Contusion

14.3.3.4. Diffuse Axonal Injury

14.3.3.5. Penetrating Injury

14.3.3.6. Second Impact Syndrome

14.3.3.7. Others

14.3.4. Others

14.4. Latin America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country

14.4.1. Brazil

14.4.1.1. Brazil Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

14.4.1.1.1. Anesthetics

14.4.1.1.2. Antagonists

14.4.1.1.3. Antibiotics

14.4.1.1.4. Antidepressants

14.4.1.1.5. Antiepileptic agents

14.4.1.1.6. Anti-inflammatory agents

14.4.1.1.7. Antioxidants/free radical scavengers

14.4.1.1.8. Cytokines

14.4.1.1.9. Ion Channel Blockers

14.4.1.1.10. Neurosteroids

14.4.1.1.11. Nutraceuticals

14.4.1.1.12. Pathway Inhibitor

14.4.1.1.13. Others (Vaccines, Toxins, etc.)

14.4.1.2. Brazil Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

14.4.1.2.1. Cerebrovascular Disease

14.4.1.2.1.1. ischemic stroke

14.4.1.2.1.2. hemorrhagic stroke

14.4.1.2.1.3. cerebrovascular anomalies

14.4.1.2.1.3.1. intracranial aneurysms

14.4.1.2.1.3.2. arteriovenous malformations

14.4.1.2.2. Neurodegenerative Disorders

14.4.1.2.2.1. Alzheimer’s Disease

14.4.1.2.2.2. Parkinson’s Disease

14.4.1.2.2.3. Amyotrophic Lateral Sclerosis

14.4.1.2.2.4. Progressive supranuclear palsy (PSP)

14.4.1.2.2.5. Corticobasal Degeneration (CBD)

14.4.1.2.2.6. Frontotemporal Dementia (FTD)

14.4.1.2.2.7. Dementia With Lewy Bodies (DLB)

14.4.1.2.2.8. Huntington’s Disease (HD)

14.4.1.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

14.4.1.2.3. Traumatic CNS Injuries

14.4.1.2.3.1. Coup-Contrecoup Brain Injury

14.4.1.2.3.2. Concussion

14.4.1.2.3.3. Brain Contusion

14.4.1.2.3.4. Diffuse Axonal Injury

14.4.1.2.3.5. Penetrating Injury

14.4.1.2.3.6. Second Impact Syndrome

14.4.1.2.3.7. Others

14.4.1.2.4. Others

14.4.2. Argentina

14.4.2.1. Argentina Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

14.4.2.1.1. Anesthetics

14.4.2.1.2. Antagonists

14.4.2.1.3. Antibiotics

14.4.2.1.4. Antidepressants

14.4.2.1.5. Antiepileptic agents

14.4.2.1.6. Anti-inflammatory agents

14.4.2.1.7. Antioxidants/free radical scavengers

14.4.2.1.8. Cytokines

14.4.2.1.9. Ion Channel Blockers

14.4.2.1.10. Neurosteroids

14.4.2.1.11. Nutraceuticals

14.4.2.1.12. Pathway Inhibitor

14.4.2.1.13. Others (Vaccines, Toxins, etc.)

14.4.2.2. Argentina Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

14.4.2.2.1. Cerebrovascular Disease

14.4.2.2.1.1. ischemic stroke

14.4.2.2.1.2. hemorrhagic stroke

14.4.2.2.1.3. cerebrovascular anomalies

14.4.2.2.1.3.1. intracranial aneurysms

14.4.2.2.1.3.2. arteriovenous malformations

14.4.2.2.2. Neurodegenerative Disorders

14.4.2.2.2.1. Alzheimer’s Disease

14.4.2.2.2.2. Parkinson’s Disease

14.4.2.2.2.3. Amyotrophic Lateral Sclerosis

14.4.2.2.2.4. Progressive supranuclear palsy (PSP)

14.4.2.2.2.5. Corticobasal Degeneration (CBD)

14.4.2.2.2.6. Frontotemporal Dementia (FTD)

14.4.2.2.2.7. Dementia With Lewy Bodies (DLB)

14.4.2.2.2.8. Huntington’s Disease (HD)

14.4.2.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

14.4.2.2.3. Traumatic CNS Injuries

14.4.2.2.3.1. Coup-Contrecoup Brain Injury

14.4.2.2.3.2. Concussion

14.4.2.2.3.3. Brain Contusion

14.4.2.2.3.4. Diffuse Axonal Injury

14.4.2.2.3.5. Penetrating Injury

14.4.2.2.3.6. Second Impact Syndrome

14.4.2.2.3.7. Others

14.4.2.2.4. Others

14.4.3. Rest of Latin America

14.4.3.1. Rest of Latin America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type

14.4.3.1.1. Anesthetics

14.4.3.1.2. Antagonists

14.4.3.1.3. Antibiotics

14.4.3.1.4. Antidepressants

14.4.3.1.5. Antiepileptic agents

14.4.3.1.6. Anti-inflammatory agents

14.4.3.1.7. Antioxidants/free radical scavengers

14.4.3.1.8. Cytokines

14.4.3.1.9. Ion Channel Blockers

14.4.3.1.10. Neurosteroids

14.4.3.1.11. Nutraceuticals

14.4.3.1.12. Pathway Inhibitor

14.4.3.1.13. Others (Vaccines, Toxins, etc.)

14.4.3.2. Rest of Latin America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application

14.4.3.2.1. Cerebrovascular Disease

14.4.3.2.1.1. ischemic stroke

14.4.3.2.1.2. hemorrhagic stroke

14.4.3.2.1.3. cerebrovascular anomalies

14.4.3.2.1.3.1. intracranial aneurysms

14.4.3.2.1.3.2. arteriovenous malformations

14.4.3.2.2. Neurodegenerative Disorders

14.4.3.2.2.1. Alzheimer’s Disease

14.4.3.2.2.2. Parkinson’s Disease

14.4.3.2.2.3. Amyotrophic Lateral Sclerosis

14.4.3.2.2.4. Progressive supranuclear palsy (PSP)

14.4.3.2.2.5. Corticobasal Degeneration (CBD)

14.4.3.2.2.6. Frontotemporal Dementia (FTD)

14.4.3.2.2.7. Dementia With Lewy Bodies (DLB)

14.4.3.2.2.8. Huntington’s Disease (HD)

14.4.3.2.2.9. Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)

14.4.3.2.3. Traumatic CNS Injuries

14.4.3.2.3.1. Coup-Contrecoup Brain Injury

14.4.3.2.3.2. Concussion

14.4.3.2.3.3. Brain Contusion

14.4.3.2.3.4. Diffuse Axonal Injury

14.4.3.2.3.5. Penetrating Injury

14.4.3.2.3.6. Second Impact Syndrome

14.4.3.2.3.7. Others

14.4.3.2.4. Others

14.5. Key Segment for Channeling Investments

14.5.1. By Country

14.5.2. By Drugs Type

14.5.3. By Application

15. Competitive Benchmarking

15.1. Market Share Analysis, 2018

15.2. Global Presence and Growth Strategies

15.2.1. Mergers and Acquisitions

15.2.2. Product Launches

15.2.3. Investments Trends

15.2.4. R&D Initiatives

16. Player Profiles

16.1. AstraZeneca

16.1.1. Company Details

16.1.2. Company Overview

16.1.3. Product Offerings

16.1.4. Key Developments

16.1.5. Financial Analysis

16.1.6. SWOT Analysis

16.1.7. Business Strategies

16.2. Astrocyte Pharmaceuticals Inc.

16.2.1. Company Details

16.2.2. Company Overview

16.2.3. Product Offerings

16.2.4. Key Developments

16.2.5. Financial Analysis

16.2.6. SWOT Analysis

16.2.7. Business Strategies

16.3. Biogen

16.3.1. Company Details

16.3.2. Company Overview

16.3.3. Product Offerings

16.3.4. Key Developments

16.3.5. Financial Analysis

16.3.6. SWOT Analysis

16.3.7. Business Strategies

16.4. Bionure Farma, S.L.

16.4.1. Company Details

16.4.2. Company Overview

16.4.3. Product Offerings

16.4.4. Key Developments

16.4.5. Financial Analysis

16.4.6. SWOT Analysis

16.4.7. Business Strategies

16.5. Genervon Biopharmaceuticals, LLC.

16.5.1. Company Details

16.5.2. Company Overview

16.5.3. Product Offerings

16.5.4. Key Developments

16.5.5. Financial Analysis

16.5.6. SWOT Analysis

16.5.7. Business Strategies

16.6. Hoffmann-La Roche Ltd

16.6.1. Company Details

16.6.2. Company Overview

16.6.3. Product Offerings

16.6.4. Key Developments

16.6.5. Financial Analysis

16.6.6. SWOT Analysis

16.6.7. Business Strategies

16.7. Neuren Pharmaceuticals

16.7.1. Company Details

16.7.2. Company Overview

16.7.3. Product Offerings

16.7.4. Key Developments

16.7.5. Financial Analysis

16.7.6. SWOT Analysis

16.7.7. Business Strategies

16.8. NeuroVive Pharmaceutical AB

16.8.1. Company Details

16.8.2. Company Overview

16.8.3. Product Offerings

16.8.4. Key Developments

16.8.5. Financial Analysis

16.8.6. SWOT Analysis

16.8.7. Business Strategies

16.9. Novartis Pharmaceuticals Corporation

16.9.1. Company Details

16.9.2. Company Overview

16.9.3. Product Offerings

16.9.4. Key Developments

16.9.5. Financial Analysis

16.9.6. SWOT Analysis

16.9.7. Business Strategies

16.10. Teva Pharmaceutical Industries Ltd

16.10.1. Company Details

16.10.2. Company Overview

16.10.3. Product Offerings

16.10.4. Key Developments

16.10.5. Financial Analysis

16.10.6. SWOT Analysis

16.10.7. Business Strategies

16.11. Other Market Players

17. Key Findings

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

**Exclusive for Multi-User and Enterprise User.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 163

    Backtrace:

    File: /var/www/html/ami/application/views/pages/reportpage.php
    Line: 163
    Function: _error_handler

    File: /var/www/html/ami/application/controllers/Report.php
    Line: 153
    Function: view

    File: /var/www/html/ami/index.php
    Line: 315
    Function: require_once